As U know, shorts have had their way with numerous biotech startups (amrn,vvus,arna...) so this should not be very different. EXCEPT...NVDQ appears to have a real and expanding application base for this unique technology. If they continue to succeed with their application results, this could expand to a very broad range of diagnostic & operational uses. Just the thought of being able, in real time, for a surgeon to know exactly when to stop excising tissue, or identify the exact edge of any invasive tumor or growth in the body is amazing. And vascular usage is still developing.
Well said, kkllfla. I saw them try the same pattern with ISRG when in it's infancy. It a lot of shorts lost their shorts as the stock continues huge upside moves each quarterly earnings. NVDQ, if it can develop its application base could very well have a similar market and earnings trajectory.
Andersongordon and kklllfla
Could not agree more with your assessments of this company's technology. I spent a couple of hours this summer listening to their investor day presentations. Their equipment is sure to become a best practice part of a growing number of different operations. It is no coincidence that the current slide in pps has been accompanied by a steady increase in short sales. The recent press release on the purchase of a Pinpoint device by Mamonides Hospital also tells an excellent story.
Not sure what informed short thesis is here - unlike early stage biotech which hemmorages cash and often has binary outcomes based on unpredictable clinical trials - here you dont have either of those concerns - you actually have growth of an installed base - which may take longer than some would like, but OK. I say "informed" b/c we shouldn't care about yahoos having done next to no due diligence, looking at a rev multiple and saying: undeserved. ISRG pinballed wildly for 2-3 yrs in its early days as a public co.